SemBioSys Demonstrates Functionality of its Safflower Produced Apo ...(iovascular diseases are the leading caus...)

Date:6/5/2008

iovascular diseases are the leading cause of mortality in developed nations and by 2010 are projected to become the leading cause of mortality worldwide. In the United States, coronary heart disease and stroke account for 70% of cardiovascular-related deaths, which claims more lives each year than the next four leading causes of death combined (cancer, respiratory disease, accidents and diabetes). Cardiovascular drugs targeting cholesterol and lipid regulation represented a $34 billion global market in 2007.

About SemBioSys Genetics Inc.

Calgary, Alberta-based SemBioSys Genetics Inc. is a biotechnology company developing protein-based pharmaceuticals for metabolic and cardiovascular diseases. The Company's technology platform allows for the production of pharmaceutical proteins in an easily scalable, very low cost (in terms of both capital and COGS) manner. The Company's lead pharmaceutical candidates, produced in the plant host safflower, are recombinant human insulin to serve the rapidly expanding global diabetes market and Apo AI(Milano), a next generation cardiovascular drug. SemBioSys also owns Botaneco Specialty Ingredients Inc., a supplier of specialty ingredients to the personal care and topical OTC and Rx markets. More information on the company can be found at http://www.sembiosys.com.

This press release contains certain forward-looking statements, including, without limitation, statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and other similar expressions which constitute "forward-looking information" within the meaning of applicable Canadian securities laws. Forward-looking statements reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements invo
'/>"/>

SOURCE SemBioSys Genetics Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related biology technology :

1. SemBioSys to present at the Needham & Company Biotechnology and Medical Technology Conference
2. SemBioSys provides update on shrimp feed additive, Immunosphere(TM)
3. SemBioSys announces first quarter 2008 financial and operational results
4. SemBioSys receives milestone payments from AVAC Ltd.
5. SemBioSys initiates toxicology study for safflower-produced insulin
6. SemBioSys announces 2007 financial and operational results
7. SemBioSys GLA Partner Enters Strategic Alliance for the Sales and Marketing of GLA-Rich Safflower Oil
8. SemBioSys awarded key patent for the production of oleosome emulsions by the European Patent Office
9. SemBioSys to present at the 10th Annual BIO CEO & Investor Conference
10. SemBioSys signs option agreement for safflower-produced food ingredient
11. SemBioSys announces 2007 third quarter results